Call 24/7:

1-800-818-4511

Ibogaine Treatment Methadone

Ibogaine Treatment for Methadone

 

Patient Blood Report Before and After Ibogaine Treatment

METHADONE

AGE:  45 

GENDER: MALE  

WEIGHT BEFORE: 126.5 KGS

WEIGHT AFTER: 122 KGS 

 

 Treatment duration

The patient underwent a 10-day ibogaine treatment program, starting on 25/04/2021 and concluding on 04/05/2021. Booster dosages were administered on 26/04/2021 and 30/04/2021 to support the treatment process. The combination of the initial treatment and booster doses aimed to facilitate the desired therapeutic effects and promote the patient’s well-being.

 

During this period, the patient’s vital signs and blood parameters were closely monitored, revealing significant changes post-treatment.

1- Blood Pressure and Heart Rate

Before ibogaine treatment, the patient exhibited varying blood pressure and heart rate values. Notably, the blood pressure ranged from 138/90 to 123/79, indicating instability. Heart rate ranged from 64 to 87 beats per minute (bpm). Heart rate also stabilized within the 78 to 88 bpm range, indicating improved cardiovascular function.

2- Glucose Levels

Pre-treatment: The patient had a fluctuating glucose level of 83, with some elevated values. Post-treatment, glucose levels became more stable, falling within the 97 to 121 mg/dL range. This improvement suggests enhanced glucose regulation.

3- SATO2

The patient consistently maintained healthy oxygen saturation levels (SATO2) throughout the treatment, with 98% or 99% values. This indicates that respiratory function remained stable and unaffected by ibogaine treatment.

4- Cell Blood Count

The patient’s cell blood count demonstrated variations before treatment, particularly in lymphocytes, neutrophils, and eosinophils. Post-treatment, these values became more consistent and normalized. Hemoglobin, hematocrit, red blood cell count, and platelet count also showed improvements, with more stable levels.

5- Biochemistry

Several biochemistry markers demonstrated noteworthy changes. Uric acid levels remained relatively stable, while glucose levels improved. Urea, creatinine, and ureic nitrogen levels fluctuated before and after treatment. Notably, there was a significant change in methadone levels, suggesting a shift in medication or substance use.

6- Lipid Profile

The lipid profile displayed changes post-treatment, with total cholesterol and HDL cholesterol levels slightly increasing while LDL cholesterol levels slightly decreased. Cholesterol VLDL levels also saw a modest increase. These changes may warrant further monitoring and dietary adjustments.

7- Liver Function

Liver function markers, including AST, ALT, total bilirubin, indirect bilirubin, direct bilirubin, LDH, and GGT, showed some fluctuations but generally remained within a reasonable range, indicating no severe liver issues associated with ibogaine treatment.

8- A1C Hemoglobin and C-Reactive Protein

The A1C haemoglobin and C-reactive protein levels demonstrated changes, with A1C haemoglobin showing an increase post-treatment, suggesting alterations in glycemic control. C-reactive protein levels also slightly increased.

 

9- Other Parameters

Total testosterone levels notably increased post-treatment. Antibodies related to Epstein-Barr virus and cytomegalovirus showed variations but generally remained stable.

9- Thyroid Function

Thyroid function markers, TSH, and Free T4 displayed changes post-treatment. TSH and T4 levels increased, indicating potential thyroid function alterations.

10- Urine Drug Test

The patient’s urine drug test results indicated changes in substance use. Notably, methadone levels decreased, benzodiazepines remained positive, and THC levels were harmful post-treatment.

 

Conclusion 

The ibogaine treatment improved notable parameters, including blood pressure stability, glucose regulation, and cell blood counts. However, some changes in lipid profiles, liver function, and thyroid markers should be closely monitored. Additionally, the shift in methadone levels suggests a potential adjustment in medication or substance use during treatment. This comprehensive analysis underscores the importance of closely monitoring patients during and after ibogaine therapy to ensure their overall health and well-being.

 

 

 

Accessibility Toolbar